Literature DB >> 19559114

Immunogenicity of an HPV-16 L2 DNA vaccine.

Inga I Hitzeroth1, Jo-Ann S Passmore, Enid Shephard, Debbie Stewart, Martin Müller, Anna-Lise Williamson, Edward P Rybicki, W Martin Kast.   

Abstract

The ability to elicit cross-neutralizing antibodies makes human papillomavirus (HPV) L2 capsid protein a possible HPV vaccine. We examined and compared the humoral response of mice immunized with a HPV-16 L2 DNA vaccine or with HPV-16 L2 protein. The L2 DNA vaccine elicited a non-neutralizing antibody response unlike the L2 protein. L2 DNA vaccination suppressed the growth of L2-expressing C3 tumor cells, which is a T cell mediated effect, demonstrating that the lack of non-neutralizing antibody induction by L2 DNA was not caused by lack of T cell immunogenicity of the construct.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559114      PMCID: PMC2767434          DOI: 10.1016/j.vaccine.2009.06.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Vaccination strategies for the prevention of cervical cancer.

Authors:  James Maclean; Edward P Rybicki; Anna-Lise Williamson
Journal:  Expert Rev Anticancer Ther       Date:  2005-02       Impact factor: 4.512

2.  DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.

Authors:  T Hanke; J Schneider; S C Gilbert; A V Hill; A McMichael
Journal:  Vaccine       Date:  1998-02       Impact factor: 3.641

3.  Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.

Authors:  Ratish Gambhira; Patti E Gravitt; Ioannis Bossis; Peter L Stern; Raphael P Viscidi; Richard B S Roden
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

4.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

Authors:  Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil D Christensen; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

5.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers.

Authors:  Kei Kawana; Toshiharu Yasugi; Tadahito Kanda; Nao Kino; Katsutoshi Oda; Satoshi Okada; Yukiko Kawana; Tomomi Nei; Toshio Takada; Sosuke Toyoshima; Akira Tsuchiya; Kazunari Kondo; Hiroyuki Yoshikawa; Osamu Tsutsumi; Yuji Taketani
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

9.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

10.  Generation and characterization of a preventive and therapeutic HPV DNA vaccine.

Authors:  Daejin Kim; Ratish Gambhira; Balasubramanyam Karanam; Archana Monie; Chien-Fu Hung; Richard Roden; T-C Wu
Journal:  Vaccine       Date:  2007-11-29       Impact factor: 3.641

View more
  13 in total

1.  Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.

Authors:  Azam Bolhassani; Martin Muller; Farzin Roohvand; Fatemeh Motevalli; Elnaz Agi; Mehdi Shokri; Mahdieh Motamedi Rad; Sahar Hosseinzadeh
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

Review 3.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07

4.  Self-Induced Back-Action Actuated Nanopore Electrophoresis (SANE) Sensor for Label-Free Detection of Cancer Immunotherapy-Relevant Antibody-Ligand Interactions.

Authors:  Sai Santosh Sasank Peri; Muhammad Usman Raza; Manoj K Sabnani; Soroush Ghaffari; Susanne Gimlin; Debra D Wawro; Jung Soo Lee; Min Jun Kim; Jon Weidanz; George Alexandrakis
Journal:  Methods Mol Biol       Date:  2022

5.  Protein transduction domain can enhance the humoral immunity and cross-protection of HPV16L2 peptide vaccines.

Authors:  Lili Li; Yantao Guo; Zelin Li; Yubai Zhou; Y I Zeng
Journal:  Biomed Rep       Date:  2016-04-07

6.  Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Authors:  Shiwen Peng; Joshua W Wang; Balasubramanyam Karanam; Chenguang Wang; Warner K Huh; Ronald D Alvarez; Sara I Pai; Chien-fu Hung; T-C Wu; Richard B S Roden
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

7.  Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.

Authors:  Shiwen Peng; Jin Qiu; Andrew Yang; Benjamin Yang; Jessica Jeang; Joshua W Wang; Yung-Nien Chang; Cory Brayton; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Cell Biosci       Date:  2016-02-25       Impact factor: 7.133

8.  In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.

Authors:  Matin Kayyal; Azam Bolhassani; Zahra Noormohammadi; Majid Sadeghizadeh
Journal:  Mol Biotechnol       Date:  2021-07-25       Impact factor: 2.695

9.  Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Authors:  Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

10.  PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.

Authors:  Shiwen Peng; Marietta Tan; Yen-Der Li; Max A Cheng; Emily Farmer; Louise Ferrall; Stephanie Gaillard; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Immunother       Date:  2020-10-27       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.